| Regulatory status |
The FDA, EMA, or other health authorities evaluate biosimilars differently than generic drugs. A product can be “biosimilar” but still not “interchangeable.” |
Check the drug label, the FDA’s “Biosimilar Drugs” page, or the EMA’s “Biosimilars” list for the latest approval and interchangeability status. |
| Clinical equivalence data |
The cornerstone of any biosimilar comparison is the clinical trial evidence that shows no clinically meaningful difference in efficacy or safety. |
Look for the key endpoint trials (e.g., reduction in proptosis, diplopia, or quality‑of‑life scores) and compare the confidence intervals. If the biosimilar’s 95% CI overlaps the reference drug’s, that’s a good sign. |
| Safety & adverse‑event profile |
Even minor differences in manufacturing can alter immunogenicity or rare side effects. |
Review the safety tables in the prescribing information. Pay particular attention to infusion‑related reactions, thyroid‑function changes, and any reports of new or unexpected events. |
| Immunogenicity |
Antibody formation can reduce efficacy or increase toxicity. |
Look for data on neutralizing antibodies and any clinical consequences noted in the trial reports. |
| Pharmacokinetics & pharmacodynamics (PK/PD) |
A biosimilar’s PK profile should be highly similar; small differences may matter if the drug has a narrow therapeutic window. |
Compare Cmax, AUC, and half‑life data. Most biosimilar approvals include a PK/PD comparability study. |
| Dosing schedule & administration |
Tepezza is given by IV infusion (e.g., 10 mg/kg, 3 mg/kg loading, then 6 mg/kg maintenance). Some biosimilars might change infusion volumes or rates. |
Verify the infusion duration, any pre‑medication requirements, and the recommended loading/maintenance doses. |
| Formulation & excipients |
Minor excipient changes can affect tolerability, especially in patients with allergies or sensitivities. |
Read the formulation section in the prescribing information for the biosimilar and compare it to Tepezza. |
| Cost & insurance coverage |
Biosimilars often offer a price advantage, but reimbursement rules vary. |
Ask your pharmacy or insurer about coverage, copays, and whether they prefer a specific biosimilar. Some payers require prior authorization. |
| Manufacturer & lot tracking |
Biosimilars may be produced by different facilities. Knowing the manufacturer can help with post‑marketing surveillance and lot‑specific reports. |
Check the brand name and manufacturer on the vial label; consult the manufacturer’s website for safety updates. |
| Patient‑reported outcomes & quality of life |
TED is a chronic condition that impacts vision and appearance. |
If available, look for studies that include PROs (e.g., the Thyroid Eye Disease Quality-of-Life questionnaire). Consistency with the reference drug in these areas is reassuring. |
| Interchangeability and substitution policies |
In the U.S., only drugs labeled “interchangeable” can be substituted by a pharmacist without the prescriber’s permission. |
Verify the biosimilar’s interchangeability status and your state’s pharmacy substitution laws. |